To include your compound in the COVID-19 Resource Center, submit it here.

EMA reveals AD drug development guidelines

EMA’s CHMP released guidance outlining diagnostic criteria and trial design for developing Alzheimer’s disease treatments, in line with FDA's guidance focused on early AD issued earlier

Read the full 262 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE